CSBR

Business Context and Reporting Period

Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended April 30, 2025
Business Overview: A technology-enabled research organization providing oncology drug discovery solutions. The company operates a proprietary bank of Patient Derived Xenograft (PDX) models ("TumorBank") and a data center ("Datacenter") to offer research services, data licensing, and SaaS tools (Lumin Bioinformatics) to biopharmaceutical companies. It also maintains a nascent internal drug discovery business.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to profitability, reporting net income of $4.7 million compared to a net loss of $7.3 million in the prior year. Operating income improved by $11.9 million.
• Revenue Growth: Total revenue increased 13.5% to $56.9 million, driven by a 3.3% increase in pharmacology services and the introduction of $4.7 million in new TOS data license revenue.
• Expense Reduction:
  • R&D Expenses: Decreased 28.5% to $6.8 million, primarily due to reduced investment in the Corellia subsidiary.
  • G&A Expenses: Decreased 15.6% to $9.3 million due to lower compensation and professional fees.
  • Cost of Revenue: Decreased 3.4% to $28.4 million due to operational efficiencies and lower outsourced lab services.
• Liquidity Improvement: Cash balance grew from $2.6 million to $9.8 million, supported by strong operating cash flow of $7.4 million.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes current cash on hand ($9.8 million) combined with expected operating cash flows is sufficient to fund operations through at least August 2026. The company continues to invest in expanding its TumorBank and developing new experimental technologies.

Management Commentary: The shift to profitability was driven by improved bookings-to-revenue conversion rates and cost discipline. The company highlighted the strategic value of its new data licensing revenue stream.

Risks and Contingencies:

• Customer Concentration: Two customers accounted for 13% and 10% of total revenue in 2025. One customer represented 19% of accounts receivable.
• Regulatory and Operational Risks: Risks include potential FDA regulation of laboratory-developed tests, facility damage, and health crises affecting the laboratory mouse colony.
• Geopolitical Exposure: The CEO resides in Israel, and the company has customers and a subsidiary there, exposing operations to regional instability.
• Capital Requirements: While currently funded, future growth may require additional capital, which could result in dilution.

Subsequent Events:

• Leadership Change: Robert Brainin was appointed CEO effective August 25, 2025, succeeding Dr. Ronnie Morris, who became Executive Chairman.
• Tax Legislation: The "One Big Beautiful Bill" enacted in July 2025 introduced changes to the U.S. tax system; the company is assessing the impact.

Investor Verification Checklist

• Sustainability of Profitability: Verify if the $4.7 million net income is a one-time result of cost-cutting (specifically R&D reduction) or a sustainable trend driven by revenue growth.
• Revenue Quality: Confirm the recurring nature of the new $4.7 million data license revenue and the stability of the top two customers (23% combined revenue).
• Working Capital Position: Monitor the negative working capital of $1.5 million and the reliance on deferred revenue ($15.4 million) to fund operations.
• Leadership Transition: Assess the impact of the CEO transition on strategic execution and customer relationships.
• Geopolitical Risk: Evaluate the specific exposure of the company's operations and key personnel to instability in Israel.